mRNA-1273.351

BIOLOGICAL3 trials

Sponsors

ModernaTX, Inc., National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19COVID-19 ImmunisationSARS-CoV-2

Phase 1

Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults

CompletedNCT04785144

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19, COVID-19 Immunisation

Start: 2021-03-31End: 2022-07-05Updated: 2024-03-18

Phase 2

Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

CompletedNCT04405076

ModernaTX, Inc.SARS-CoV-2

Start: 2020-05-29End: 2021-10-28Updated: 2022-12-30

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

CompletedNCT05289037

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2022-03-30End: 2023-11-27Updated: 2025-10-17

Related Papers

Effect of Omicron BA.1-based compared to prototype booster mRNA vaccination on incidence of COVID-19 in the COVAIL trial

Vaccine2025-09-09

Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost.

2025-01-177 citations

Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases

Nature Communications2024-08-2931 citations

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial.

2023-08-2839 citations

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19.

2022-11-154 citations

Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.

2022-10-06121 citations

Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial

Nature Medicine2022-03-03100 citations

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults.

2022-02-0847 citations

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Nature Medicine2021-09-15446 citations

A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.

2021-02-09175 citations

Understanding COVID-19 Vaccines and Their Development

Journal of Bone and Joint Surgery2020-07-316 citations

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

New England Journal of Medicine2020-07-143412 citations